Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 135

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Mechanism of staphylococcal resistance to clinically relevant antibiotics

Brdová, Daniela, Ruml, Tomáš, Viktorová, Jitka · 2024 · Drug Resistance Updates

Abstract

Staphylococcus aureus, a notorious pathogen with versatile virulence, poses a significant challenge to current antibiotic treatments due to its ability to develop resistance mechanisms against a variety of clinically relevant antibiotics. In this comprehensive review, we carefully dissect the resistance mechanisms employed by S. aureus against various antibiotics commonly used in clinical settings. The article navigates through intricate molecular pathways, elucidating the mechanisms by which S. aureus evades the therapeutic efficacy of antibiotics, such as β-lactams, vancomycin, daptomycin, linezolid, etc. Each antibiotic is scrutinised for its mechanism of action, impact on bacterial physiology, and the corresponding resistance strategies adopted by S. aureus. By synthesising the knowledge surrounding these resistance mechanisms, this review aims to serve as a comprehensive resource that provides a foundation for the development of innovative therapeutic strategies and alternative treatments for S. aureus infections. Understanding the evolving landscape of antibiotic resistance is imperative for devising effective countermeasures in the battle against this formidable pathogen.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drup.2024.101147

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 199

  1. Lai, 2022, Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches – an overview, Adv. Drug Deliv. Rev., 181, 10.1016/j.addr.2021.114078 · DOI
  2. Davies, 2010, Origins and evolution of antibiotic resistance, Microbiol. Mol. Biol. Rev., 74, 417, 10.1128/MMBR.00016-10 · DOI · Paper page
  3. Ratia, 2022, Gold-derived molecules as new antimicrobial agents, Front. Microbiol., 13, 10.3389/fmicb.2022.846959 · DOI
  4. Jensen, 2009, Genetics of antimicrobial resistance in Staphylococcus aureus, Future Microbiol., 4, 565, 10.2217/fmb.09.30 · DOI · Paper page
  5. Rammelkamp, 1942, Resistance of Staphylococcus aureus to the Action of Penicillin. Proceedings of the Society for, Exp. Biol. Med., 51, 386, 10.3181/00379727-51-13986 · DOI · Paper page
  6. Peacock, 2015, Mechanisms of methicillin resistance in Staphylococcus aureus, Annu. Rev. Biochem., 84, 577, 10.1146/annurev-biochem-060614-034516 · DOI · Paper page
  7. Barber, 1961, Methicillin-resistant Staphylococci, J. Clin. Pathol., 14, 385, 10.1136/jcp.14.4.385 · DOI · Paper page
  8. Bishara, 2012, Healthcare-associated vs. hospital-acquired Staphylococcus aureus bacteremia, Int. J. Infect. Dis., 16, e457, 10.1016/j.ijid.2012.02.009 · DOI
  9. Tsuji, 2007, Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents, Diagn. Microbiol. Infect. Dis., 58, 41, 10.1016/j.diagmicrobio.2006.10.021 · DOI
  10. Newman, 2015, Chapter 5 - Natural Products as Pharmaceuticals and Sources for Lead Structures, 101
  11. Guo, 2020, Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus, Front. Cell. Infect. Microbiol., 10, 10.3389/fcimb.2020.00107 · DOI · Paper page
  12. Lade, 2022, Molecular basis of non-β-lactam antibiotics resistance in Staphylococcus aureus, Antibiot. (Basel), 11
  13. Kahlmeter, 2019, Point-counterpoint: differences between the european committee on antimicrobial susceptibility testing and clinical and laboratory standards institute recommendations for reporting antimicrobial susceptibility results, J. Clin. Microbiol., 57, 10.1128/JCM.01129-19 · DOI
  14. Costa, 2017, Evolution of antimicrobial resistance in Europe: a factual review, J. Allergy Ther., 8, 1
  15. Fernández, 2011, Creeping baselines and adaptive resistance to antibiotics, Drug Resist. Updates, 14, 1, 10.1016/j.drup.2011.01.001 · DOI · Paper page
  16. Ramirez, 2010, Aminoglycoside modifying enzymes, Drug Resist. Updates, 13, 151, 10.1016/j.drup.2010.08.003 · DOI · Paper page
  17. Douglas, 2023, Staph wars: the antibiotic pipeline strikes back, Microbiol. (Read. ), 169
  18. Chen, 2023, A review of current antibiotic resistance and promising antibiotics with novel modes of action to combat antibiotic resistance, Arch. Microbiol., 205, 356, 10.1007/s00203-023-03699-2 · DOI
  19. Navratna, 2010, Molecular basis for the role of Staphylococcus aureus Penicillin Binding Protein 4 in Antimicrobial Resistance, J. Bacteriol., 192, 134, 10.1128/JB.00822-09 · doi:10.1128/jb.00822-09
  20. Berti, 2013, β-lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 57, 5005, 10.1128/AAC.00594-13 · DOI
  21. Pinho, 2000, Cloning, characterization, and inactivation of the gene pbpC, encoding penicillin-binding protein 3 of Staphylococcus aureus, J. Bacteriol., 182, 1074, 10.1128/JB.182.4.1074-1079.2000 · DOI
  22. Henze, 1995, Staphylococcus aureus penicillin-binding protein 4 and intrinsic beta-lactam resistance, Antimicrob. Agents Chemother., 39, 2415, 10.1128/AAC.39.11.2415 · DOI
  23. Fisher, 2016, β-lactam resistance mechanisms: gram-positive bacteria and Mycobacterium tuberculosis, Cold Spring Harb. Perspect. Med., 6, 10.1101/cshperspect.a025221 · DOI
  24. da Costa, 2018, PBP4: a new perspective on Staphylococcus aureus β-Lactam Resistance, Microorg. (Basel), 6, 57, 10.3390/microorganisms6030057 · DOI
  25. Ferrer-González, 2017, β-lactam antibiotics with a high affinity for PBP2 act Synergistically with the FtsZ-Targeting Agent TXA707 against Methicillin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 61, e00863, 10.1128/AAC.00863-17 · DOI
  26. Lowy, 2003, Antimicrobial resistance: the example of Staphylococcus aureus, J. Clin. Investig., 111, 1265, 10.1172/JCI18535 · DOI · Paper page
  27. Alexander, 2023, Structural basis of broad-spectrum β-lactam resistance in Staphylococcus aureus, Nat. (Lond. ), 613, 375, 10.1038/s41586-022-05583-3 · DOI
  28. Hartman, 1984, Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus, J. Bacteriol., 158, 513, 10.1128/jb.158.2.513-516.1984 · DOI · Paper page
  29. Utsui, 1985, Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 28, 397, 10.1128/AAC.28.3.397 · DOI · Paper page
  30. Strynadka, 2002, Structural basis for the β lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus, Nat. Struct. Biol., 9, 870
  31. Zuniga, 2020, Expression of genes encoding resistance in Staphylococcus spp. isolated from bovine subclinical mastitis in Brazil, J. Infect. Dev. Ctries., 14, 772, 10.3855/jidc.12611 · doi:10.3855/jidc.12611
  32. Uddin, 2017, Associations between resistance phenotype and gene expression in response to serial exposure to oxacillin and ciprofloxacin in Staphylococcus aureus, Lett. Appl. Microbiol., 65, 462, 10.1111/lam.12808 · DOI
  33. Rosato, 2003, mecA-blaZ corepressors in clinical Staphylococcus aureus isolates, Antimicrob. Agents Chemother., 47, 1460, 10.1128/AAC.47.4.1460-1463.2003 · DOI
  34. Paterson, 2013, The emergence of mecC methicillin-resistant Staphylococcus aureus, Trends Microbiol. (Regul. Ed. ), 22, 42, 10.1016/j.tim.2013.11.003 · DOI
  35. McClure, 2020, A novel assay for detection of methicillin-resistant Staphylococcus aureus directly from clinical samples, Front. Microbiol., 11
  36. Lozano, 2020, Human mecC-Carrying MRSA: clinical implications and risk factors, Microorg. (Basel), 8, 1615, 10.3390/microorganisms8101615 · DOI
  37. Hryniewicz, 2017, Borderline oxacillin-resistant Staphylococcus aureus (BORSA) - a more common problem than expected?, J. Med. Microbiol., 66, 10.1099/jmm.0.000585 · doi:10.1099/jmm.0.000585
  38. Nomura, 2020, A class A β-lactamase produced by borderline oxacillin-resistant Staphylococcus aureus hydrolyses oxacillin, J. Glob. Antimicrob. Resist., 22, 244, 10.1016/j.jgar.2020.03.002 · DOI
  39. Gitman, 2021, Modified methicillin-resistant Staphylococcus aureus detected in neonatal intensive care patients, J. Antimicrob. Chemother., 76, 2774, 10.1093/jac/dkab266 · doi:10.1093/jac/dkab266
  40. Memmi, 2008, Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains, Antimicrob. Agents Chemother., 52, 3955, 10.1128/AAC.00049-08 · DOI · Paper page
  41. Hamilton, 2017, High-level resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-binding Protein 4 (PBP4), Antimicrob. Agents Chemother., 61, 10.1128/AAC.02727-16 · DOI
  42. Argudín, 2018, Genetic diversity among staphylococcus aureus isolates showing oxacillin and/or cefoxitin resistance not linked to the presence of mec Genes, Antimicrob. Agents Chemother., 62, 10.1128/AAC.00091-18 · DOI · Paper page
  43. Chatterjee, 2017, PBP4 Mediates β-lactam resistance by altered function, Antimicrob. Agents Chemother., 61, 10.1128/AAC.00932-17 · DOI
  44. Duplessis, 2011, Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA), Clin. Med. Rev. Ther., 3, 1
  45. Acebrón, 2015, The allosteric site for the nascent cell wall in penicillin-binding protein 2a: an achilles' heel of methicillin-resistant Staphylococcus aureus, Curr. Med. Chem., 22, 1678, 10.2174/0929867322666150311150215 · DOI
  46. Greninger, 2016, Whole-genome sequencing of methicillin-resistant Staphylococcus aureus resistant to fifth-generation cephalosporins reveals potential Non-mecA Mechanisms of Resistance, PloS One, 11, 10.1371/journal.pone.0149541 · DOI · Paper page
  47. Chan, 2015, Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 59, 2960, 10.1128/AAC.05004-14 · doi:10.1128/aac.05004-14
  48. Liu, 2021, Emerging resistance mechanisms for 4 types of common anti-MRSA antibiotics in Staphylococcus aureus: a comprehensive review, Microb. Pathog., 156, 10.1016/j.micpath.2021.104915 · DOI · Paper page
  49. Zhanel, 2010, New Lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin, Drugs (N. Y., N. Y. ), 70, 859
  50. Szemraj, 2022, Vancomycin heteroresistance among methicillin-resistant clinical isolates S. haemolyticus, S. hominis, S. simulans, and S. warneri, Braz. J. Microbiol.
  51. Peschel, 2000, The d-alanine residues ofstaphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes, Antimicrob. Agents Chemother., 44, 2845, 10.1128/AAC.44.10.2845-2847.2000 · DOI · Paper page
  52. Beauregard, 1995, Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics, Antimicrob. Agents Chemother., 39, 781, 10.1128/AAC.39.3.781 · DOI · Paper page
  53. Zhanel, 2012, Oritavancin: mechanism of action, Clin. Infect. Dis., 54, S214, 10.1093/cid/cir920 · DOI · Paper page
  54. Cong, 2019, Vancomycin resistant Staphylococcus aureus infections: a review of case updating and clinical features, J. Adv. Res., 21
  55. Perichon, 2009, VanA-type vancomycin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 4580, 10.1128/AAC.00346-09 · DOI · Paper page
  56. Jacoby, G. Correction to: Transmissible Antibiotic Resistance. 2019. · doi:10.1007/978-3-319-78538-7_25
  57. Thaker, 2015, Vancomycin-variable enterococci can give rise to constitutive resistance during antibiotic therapy, Antimicrob. Agents Chemother., 59, 1405, 10.1128/AAC.04490-14 · DOI
  58. Melo-Cristino, 2013, First case of infection with vancomycin-resistant Staphylococcus aureus in Europe, Lancet, 382, 205, 10.1016/S0140-6736(13)61219-2 · DOI
  59. Hiramatsu, 2014, Vancomycin-intermediate resistance in Staphylococcus aureus, J. Glob. Antimicrob. Resist., 2, 213, 10.1016/j.jgar.2014.04.006 · DOI
  60. Delaune, 2012, The WalKR system controls major Staphylococcal virulence genes and is involved in triggering the host inflammatory response, Infect. Immun., 80, 3438, 10.1128/IAI.00195-12 · DOI · Paper page
  61. Yin, 2006, VraSR Two-component regulatory system and its role in induction of pbp2 and vraSR expression by cell wall antimicrobials in Staphylococcus aureus, Antimicrob. Agents Chemother., 50, 336, 10.1128/AAC.50.1.336-343.2006 · DOI
  62. Chen, 2021, The role of graRS in regulating virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus, Front. Microbiol., 12
  63. Zhu, 2021, A novel mutation of walK confers vancomycin-intermediate resistance in methicillin-susceptible Staphylococcus aureus, Int. J. Med. Microbiol., 311, 10.1016/j.ijmm.2021.151473 · DOI
  64. Crotty, 2016, New gram-positive agents: the next generation of oxazolidinones and Lipoglycopeptides, J. Clin. Microbiol., 54, 2225, 10.1128/JCM.03395-15 · DOI
  65. Gonzalez-Ruiz, 2011, Clinical experience with daptomycin in Europe: The first 2.5 years, J. Antimicrob. Chemother., 66, 912, 10.1093/jac/dkq528 · DOI
  66. Grein, 2020, Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids, Nat. Commun., 11, 10.1038/s41467-020-15257-1 · DOI · Paper page
  67. Heidary, 2018, Daptomycin, J. Antimicrob. Chemother., 73, 1, 10.1093/jac/dkx349 · DOI · Paper page
  68. Gray, 2020, More than a pore: a current perspective on the in vivo mode of action of the lipopeptide antibiotic daptomycin, Antibiotics, 9, 10.3390/antibiotics9010017 · DOI
  69. Grünewald, 2004, Synthesis and derivatization of daptomycin: a chemoenzymatic route to acidic lipopeptide antibiotics, J. Am. Chem. Soc., 126, 17025, 10.1021/ja045455t · DOI
  70. Gómez Casanova, 2017, Mechanisms of resistance to daptomycin in Staphylococcus aureus, Rev. Esp. Quimioter., 30, 391
  71. Gutiérrez-Chávez, 2021, The ecological roles of microbial lipopeptides: Where are we going?, Comput. Struct. Biotechnol. J., 19, 1400, 10.1016/j.csbj.2021.02.017 · DOI
  72. Miller, 2016, Mechanism of action and resistance to daptomycin in Staphylococcus aureus and Enterococci, Cold Spring Harb. Perspect. Med., 6, 10.1101/cshperspect.a026997 · DOI · Paper page
  73. Bayer, 2015, Frequency and distribution of single-nucleotide polymorphisms within mprF in methicillin-resistant staphylococcus aureus clinical isolates and their role in cross-resistance to daptomycin and host defense antimicrobial peptides, Antimicrob. Agents Chemother., 59, 4930, 10.1128/AAC.00970-15 · DOI
  74. Cafiso, 2014, dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus, Int. J. Antimicrob. Agents, 43, 26, 10.1016/j.ijantimicag.2013.10.001 · DOI
  75. Kattke, M., Gosschalk, J., Martinez, O., Kumar, G., Gale, R., Cascio, D., Sawaya, M., Phillips, M., Brown, E., Clubb, R., 2018. Structure and mechanism of TagA, a novel membrane-associated glycosyltransferase that produces wall teichoic acids in pathogenic bacteria; 2018. DOI: 10.1101/507483 10.1101/507483.. · DOI
  76. Bertsche, 2013, Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates, PLoS One, 8, 10.1371/journal.pone.0067398 · DOI
  77. Koprivnjak, 2011, Characterization of Staphylococcus aureus Cardiolipin Synthases 1 and 2 and their contribution to accumulation of cardiolipin in stationary phase and within phagocytes, J. Bacteriol., 193, 4134, 10.1128/JB.00288-11 · DOI
  78. Lasek-Nesselquist, 2019, Insights into the evolution of staphylococcus aureus daptomycin resistance from an in vitro bioreactor model, Front. Microbiol., 10, 345, 10.3389/fmicb.2019.00345 · DOI
  79. Zhang, 2014, Cardiolipin prevents membrane translocation and permeabilization by daptomycin, J. Biol. Chem., 289
  80. Bæk, 2015, Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene, Antimicrob. Agents Chemother., 59, 6983, 10.1128/AAC.01303-15 · DOI
  81. Howden, 2011, Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR, PLoS Pathog., 7, 10.1371/journal.ppat.1002359 · DOI · Paper page
  82. Pader, 2016, Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids, Nat. Microbiol., 2, 10.1038/nmicrobiol.2016.194 · DOI
  83. Pee, C., Pader, V., Ledger, E., Edwards, A., 2018. , A FASII inhibitor prevents staphylococcal evasion of daptomycin by inhibiting phospholipid decoy production; 2018. DOI: 10.1101/427989.. · doi:10.1101/427989
  84. Krause, 2016, Aminoglycosides: an overview, Cold Spring Harb. Perspect. Med., 6, 10.1101/cshperspect.a027029 · DOI · Paper page
  85. Ramirez, 2017, Amikacin: uses, resistance, and prospects for inhibition, Mol. (Basel, Switz. ), 22, 2267, 10.3390/molecules22122267 · DOI · Paper page
  86. Stankowicz, M., Ibrahim, J., Brown, D., 2015. Once-daily aminoglycoside dosing: An update on current literature. American Journal of Health-System Pharmacy: AJHP: Official Journal of The American Society of Health-System Pharmacists 2015, 72, 1357-1364. DOI: 10.2146/ajhp140564. · doi:10.2146/ajhp140564
  87. Serio, 2018, Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation, EcoSal, 8
  88. Zhanel, 2012, Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin, Expert Rev. Anti-Infect. Ther., 10, 459, 10.1586/eri.12.25 · DOI · Paper page
  89. Mingeot-Leclercq, 1999, Aminoglycosides: activity and resistance, Antimicrob. Agents Chemother., 43, 727, 10.1128/AAC.43.4.727 · DOI · Paper page
  90. Ramirez, 2017, Amikacin: uses, resistance, and prospects for inhibition, Molecules, 22, 2267, 10.3390/molecules22122267 · DOI · Paper page
  91. Serio, 2018, Aminoglycoside revival: review of a historically important class of antimicrobials undergoing rejuvenation, EcoSal, 8
  92. Kong, 2020, Exploration of antibiotic activity of aminoglycosides, in particular ribostamycin alone and in combination with ethylenediaminetetraacetic acid against pathogenic bacteria, Front. Microbiol., 11, 1718, 10.3389/fmicb.2020.01718 · DOI
  93. Webster, 2022, A mini-review: environmental and metabolic factors affecting aminoglycoside efficacy, World J. Microbiol. Biotechnol., 39
  94. Krause, 2016, Aminoglycosides: an overview, Cold Spring Harb. Perspect. Med., 6, a027029, 10.1101/cshperspect.a027029 · DOI · Paper page
  95. Ramirez, 2010, Aminoglycoside modifying enzymes, Drug Resist. Updates, 13, 151, 10.1016/j.drup.2010.08.003 · DOI · Paper page
  96. Doi, 2016, Aminoglycoside resistance: the emergence of acquired 16s ribosomal RNA methyltransferases, Infect. Dis. Clin. North Am., 30, 523, 10.1016/j.idc.2016.02.011 · DOI · Paper page
  97. Khosravi, 2017, Distribution of genes encoding resistance to aminoglycoside modifying enzymes in methicillin-resistant Staphylococcus aureus (MRSA) strains, Kaohsiung J. Med. Sci., 33, 587, 10.1016/j.kjms.2017.08.001 · DOI
  98. Szymanek-Majchrzak, 2018, Resistance to aminoglycosides of methicillin-resistant strains of staphylococcus aureus, originating in the surgical and transplantation wards of the warsaw clinical center—a retrospective analysis, Transplant. Proc., 50, 2170, 10.1016/j.transproceed.2018.02.158 · DOI · Paper page
  99. Costa, 2019, High Prevalence of the aac(6′)-Ie-aph(2′′)-Ia Gene in Hospital Isolates of Enterococcus faecalis Co-Resistant to Gentamicin and Penicillin, Microb. Drug Resist., 25, 1275, 10.1089/mdr.2018.0466 · DOI
  100. Frase, 2012, Revisiting the nucleotide and aminoglycoside substrate specificity of the bifunctional aminoglycoside Acetyltransferase(6′)-Ie/Aminoglycoside Phosphotransferase(2″)-Ia Enzyme, J. Biol. Chem., 287, 43262, 10.1074/jbc.M112.416453 · DOI
  101. Zárate, 2018, Overcoming aminoglycoside enzymatic resistance: design of novel antibiotics and inhibitors, Molecules, 23, 10.3390/molecules23020284 · DOI
  102. Shakya, 2010, Nucleotide selectivity of antibiotic kinases, Antimicrob. Agents Chemother., 54, 1909, 10.1128/AAC.01570-09 · DOI
  103. Kanchugal P, 2020, Structural recognition of spectinomycin by resistance enzyme ANT(9) from Enterococcus faecalis, Antimicrob. Agents Chemother., 64, 10.1128/AAC.00371-20 · DOI
  104. Cox, 2018, Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes, ACS Infect. Dis., 4, 980, 10.1021/acsinfecdis.8b00001 · DOI
  105. Rocha, 2021, Inhibition of Aminoglycoside 6′-N-acetyltransferase Type Ib (AAC(6′)-Ib): structure–activity relationship of substituted pyrrolidine pentamine derivatives as inhibitors, Biomedicines, 9, 1218, 10.3390/biomedicines9091218 · doi:10.3390/biomedicines9091218
  106. Labby, 2013, Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections, Future Med. Chem., 5, 1285, 10.4155/fmc.13.80 · DOI
  107. Quirke, 2022, Structure-Activity Relationships for 5'' Modifications of 4,5-Aminoglycoside Antibiotics, ChemMedChem, 17, 10.1002/cmdc.202200120 · DOI
  108. Yan, 2022, Design, Synthesis, and Bioassay of 2′-Modified Kanamycin A, Molecules, 27, 10.3390/molecules27217482 · DOI
  109. Costa, 2020, Development of peptides that inhibit aminoglycoside-modifying enzymes and β-lactamases for control of resistant bacteria, Curr. Protein Pept. Sci., 21, 1011, 10.2174/1389203721666200915113630 · doi:10.2174/1389203721666200915113630
  110. Williams, 1979, Synthesis of a tight-binding, multisubstrate analog inhibitor of gentamicin acetyltransferase I, J. Antibiot. (Tokyo), 32, 1147, 10.7164/antibiotics.32.1147 · doi:10.7164/antibiotics.32.1147
  111. Wang, 2022, Antibiotic combination therapy: a strategy to overcome bacterial resistance to aminoglycoside antibiotics, Front. Pharmacol., 13
  112. Grossman, 2016, Tetracycline Antibiotics and Resistance, Cold Spring Harb. Perspect. Med., 6, a025387, 10.1101/cshperspect.a025387 · DOI · Paper page
  113. Duggar, 1948, Aureomycin; a product of the continuing search for new antibiotics. Annuals, N. Y. Acad. Sci., 51, 177, 10.1111/j.1749-6632.1948.tb27262.x · DOI · Paper page
  114. Finlay, 1950, Terramycin, a new antibiotic, Science, 111, 85, 10.1126/science.111.2874.85.a · doi:10.1126/science.111.2874.85.a
  115. Nelson, 2011, The history of the tetracyclines. Annuals, N. Y. Acad. Sci., 1241, 17, 10.1111/j.1749-6632.2011.06354.x · DOI · Paper page
  116. McCormick, 1957, A new family of antibiotics: the demethyltetracyclines, J. Am. Chem. Soc., 79, 4561, 10.1021/ja01573a089 · doi:10.1021/ja01573a089
  117. Rusu, 2021, The development of third-generation tetracycline antibiotics and new perspectives, Pharmaceutics, 13, 10.3390/pharmaceutics13122085 · DOI · Paper page
  118. Stein, 2006, Tigecycline: a critical analysis, Clin. Infect. Dis., 43, 518, 10.1086/505494 · DOI · Paper page
  119. Gallagher, 2019, Omadacycline: a modernized tetracycline, Clin. Infect. Dis., 69, S1, 10.1093/cid/ciz394 · doi:10.1093/cid/ciz394
  120. Coppock, 2018, FDA approves eravacycline for adults with complicated intra-abdominal infections, Pharmacy
  121. Durães, 2019, Omadacycline: a newly approved antibacterial from the class of tetracyclines, Pharm. (Basel), 12
  122. Wilson, 2020, Target protection as a key antibiotic resistance mechanism, Nat. Rev. Microbiol., 18, 637, 10.1038/s41579-020-0386-z · DOI · Paper page
  123. Ero, 2021, Ribosome protection proteins—“New” players in the global arms race with antibiotic-resistant pathogens, Int. J. Mol. Sci., 22, 10.3390/ijms22105356 · DOI
  124. Arenz, 2015, Cryo-EM structure of the tetracycline resistance protein TetM in complex with a translating ribosome at 3.9-å resolution, Proc. Natl. Acad. Sci., 112, 5401, 10.1073/pnas.1501775112 · DOI
  125. Burdett, 1996, Tet(M)-promoted release of tetracycline from ribosomes is GTP dependent, J. Bacteriol., 178, 3246, 10.1128/jb.178.11.3246-3251.1996 · DOI · Paper page
  126. Nguyen, 2014, Tetracycline antibiotics and resistance mechanisms, Biol. Chem., 395, 559, 10.1515/hsz-2013-0292 · DOI · Paper page
  127. Zhang, 2022, Dissemination and prevalence of plasmid-mediated high-level tigecycline resistance gene tet (X4), Front. Microbiol., 13
  128. Kannan, 2011, Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. Annuals, N. Y. Acad. Sci., 1241, 33, 10.1111/j.1749-6632.2011.06315.x · DOI
  129. Miklasińska-Majdanik, 2021, Mechanisms of resistance to macrolide antibiotics among Staphylococcus aureus, Antibiotics, 10, 1406, 10.3390/antibiotics10111406 · DOI · Paper page
  130. Schwarz, 2016, Lincosamides, streptogramins, phenicols, and pleuromutilins: mode of action and mechanisms of resistance, Cold Spring Harb. Perspect. Med., 6, 10.1101/cshperspect.a027037 · DOI
  131. Tenson, 2003, The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome, J. Mol. Biol., 330, 1005, 10.1016/S0022-2836(03)00662-4 · DOI · Paper page
  132. Feßler, 2018, Mobile macrolide resistance genes in staphylococci, Plasmid, 99, 2, 10.1016/j.plasmid.2018.05.001 · DOI
  133. Galarion, 2023, The native ABC-F proteins of Staphylococcus aureus do not contribute to intrinsic resistance against ribosome-targeting antibacterial drugs, J. Antimicrob. Chemother., 78, 2601, 10.1093/jac/dkad238 · DOI
  134. Sharkey, 2016, ABC-F proteins mediate antibiotic resistance through ribosomal protection, mBio, 7, 10.1128/mBio.01975-15 · DOI · Paper page
  135. Ero, 2019, Ribosome protection by ABC-F proteins-molecular mechanism and potential drug design, Protein Sci., 28, 684, 10.1002/pro.3589 · DOI
  136. Vimberg, 2020, Ribosome-mediated attenuation of vga(A) expression is shaped by the antibiotic resistance specificity of Vga(A) Protein Variants, Antimicrob. Agents Chemother., 64, 10.1128/AAC.00666-20 · DOI
  137. Izard, 2001, Structural basis for chloramphenicol tolerance in Streptomyces venezuelae by chloramphenicol phosphotransferase activity, Protein Sci., 10, 1508, 10.1002/pro.101508 · doi:10.1002/pro.101508
  138. Foti, 2021, Oxazolidinone antibiotics: chemical, biological and analytical aspects, Molecules, 26, 10.3390/molecules26144280 · DOI · Paper page
  139. Paukner, 2017, Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance, Cold Spring Harb. Perspect. Med., 7, 10.1101/cshperspect.a027110 · DOI · Paper page
  140. Zhanel, 2021, Lefamulin: a novel oral and intravenous pleuromutilin for the treatment of community-acquired bacterial pneumonia, Drugs, 81, 233, 10.1007/s40265-020-01443-4 · DOI
  141. Mohamad, 2022, Sal-type ABC-F proteins: intrinsic and common mediators of pleuromutilin resistance by target protection in staphylococci, Nucleic Acids Res., 50, 2128, 10.1093/nar/gkac058 · DOI
  142. Khoshnood, 2019, A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus, Biomed. Pharmacother., 109, 1809, 10.1016/j.biopha.2018.10.131 · DOI
  143. Westgeest, 2024, Eradication of community-onset Methicillin-resistant Staphylococcus aureus carriage: a narrative review, Clin. Microbiol. Infect., 10.1016/j.cmi.2024.01.003 · DOI
  144. Tucaliuc, 2019, Mupirocin: applications and production, Biotechnol. Lett., 41, 495, 10.1007/s10529-019-02670-w · doi:10.1007/s10529-019-02670-w
  145. Dadashi, 2020, Mupirocin resistance in Staphylococcus aureus: a systematic review and meta-analysis, J. Glob. Antimicrob. Resist., 20, 238, 10.1016/j.jgar.2019.07.032 · doi:10.1016/j.jgar.2019.07.032
  146. Wang, 2022, Methicillin-resistant Staphylococcus aureus in China: a multicentre longitudinal study and whole-genome sequencing, Emerg. Microbes Infect., 11, 532, 10.1080/22221751.2022.2032373 · DOI · Paper page
  147. González-López, 2024, Structures of the Staphylococcus aureus ribosome inhibited by fusidic acid and fusidic acid cyclopentane, Sci. Rep., 14, 10.1038/s41598-024-64868-x · DOI
  148. Fernandes, 2016, Fusidic acid: a bacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections, Cold Spring Harb. Perspect. Med., 6, a025437, 10.1101/cshperspect.a025437 · DOI
  149. Lesher, 1962, 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents, J. Med. Pharm. Chem., 5, 1063, 10.1021/jm01240a021 · DOI · Paper page
  150. Correia, 2017, Mechanisms of quinolone action and resistance: where do we stand?, J. Med. Microbiol., 66, 551, 10.1099/jmm.0.000475 · DOI · Paper page
  151. Baggio, 2021, Fluoroquinolone antibiotics and adverse events, Aust. Prescr., 44, 161, 10.18773/austprescr.2021.035 · DOI · Paper page
  152. Aldred, 2014, Mechanism of quinolone action and resistance, Biochemistry, 53, 1565, 10.1021/bi5000564 · DOI · Paper page
  153. Tang, 2023, Quinolone antibiotics: resistance and therapy, Infect. Drug Resist., 16, 811, 10.2147/IDR.S401663 · DOI
  154. Shariati, 2022, The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic, Front. Public Health, 10, 10.3389/fpubh.2022.1025633 · DOI · Paper page
  155. Pham, 2019, Quinolone antibiotics, MedChemComm, 10, 1719, 10.1039/C9MD00120D · DOI · Paper page
  156. Huynh, 2023, Genomic alterations involved in fluoroquinolone resistance development in Staphylococcus aureus, PLoS One, 18, 10.1371/journal.pone.0287973 · DOI
  157. Hamza, 2023, Molecular investigation of quinolone-resistant genes among clinical Staphylococcus aureus isolates in Babylon hospitals, Med. J. Babylon., 20, 553, 10.4103/MJBL.MJBL_347_23 · DOI
  158. Masters, 2003, Trimethoprim-sulfamethoxazole revisited, Arch. Intern. Med., 163, 402, 10.1001/archinte.163.4.402 · DOI · Paper page
  159. Stevens, 2014, Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America, Clin. Infect. Dis., 59, e10, 10.1093/cid/ciu296 · DOI · Paper page
  160. Haseeb, 2022, Trimethoprim-Sulfamethoxazole (Bactrim) dose optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: a systematic review, Int. J. Environ. Res. Public Health, 19, 10.3390/ijerph19052833 · DOI
  161. McCarter, 2017, Antibiotics: challenges, mechanisms, opportunities Written by Christopher Walsh, PhD and Timothy Wencewicz, PhD, Lab. Med., 48, 10.1093/labmed/lmw070 · doi:10.1093/labmed/lmw070
  162. Goldberg, 2012, Contemporary unconventional clinical use of co-trimoxazole, Clin. Microbiol. Infect., 18, 8, 10.1111/j.1469-0691.2011.03613.x · DOI
  163. Sensi, 1960, A new antibiotic of the rifomycin family, Farm. Sci., 15, 228
  164. Hardie, 2022, JMM profile: rifampicin: a broad-spectrum antibiotic, J. Med. Microbiol., 71, 10.1099/jmm.0.001566 · doi:10.1099/jmm.0.001566
  165. Wang, 2019, Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant Staphylococcus aureus strains selected in vitro, BMC Microbiol., 19, 220, 10.1186/s12866-019-1573-9 · DOI
  166. Zheng, 2021, Resistance profiles and biological characteristics of rifampicin-resistant Staphylococcus aureus small-colony variants, Infect. Drug Resist., 14, 1527, 10.2147/IDR.S301863 · DOI
  167. Zhang, 2023, The development of variation-based rifampicin resistance in Staphylococcus aureus deciphered through genomic and transcriptomic study, J. Hazard. Mater., 442, 10.1016/j.jhazmat.2022.130112 · DOI
  168. Lee, 2022, Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea, J. Glob. Antimicrob. Resist., 28, 43, 10.1016/j.jgar.2021.12.005 · DOI
  169. Dashtbani-Roozbehani, 2021, Efflux pump mediated antimicrobial resistance by Staphylococci in Health-Related Environments: Challenges and the Quest for Inhibition, Antibiot. (Basel), 10
  170. Alnaseri, 2015, Inducible expression of a resistance-nodulation-division-type efflux pump in Staphylococcus aureus provides resistance to linoleic and arachidonic acids, J. Bacteriol., 197, 1893, 10.1128/JB.02607-14 · DOI
  171. Ding, 2023, Role of efflux pumps, their inhibitors, and regulators in colistin resistance, Front. Microbiol., 14, 10.3389/fmicb.2023.1207441 · DOI
  172. Nishino, 2021, Function and Inhibitory Mechanisms of Multidrug Efflux Pumps, Front. Microbiol., 12, 10.3389/fmicb.2021.737288 · DOI · Paper page
  173. Lekshmi, 2018, Modulation of antimicrobial efflux pumps of the major facilitator superfamily in Staphylococcus aureus, AIMS Microbiol., 4, 1, 10.3934/microbiol.2018.1.1 · DOI
  174. Floyd, 2010, LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus, Antimicrob. Agents Chemother., 54, 5406, 10.1128/AAC.00580-10 · DOI · Paper page
  175. Vimberg, 2020, VanZ reduces the binding of lipoglycopeptide antibiotics to Staphylococcus aureus and Streptococcus pneumoniae Cells, Front. Microbiol., 11, 566, 10.3389/fmicb.2020.00566 · DOI
  176. Liu, 2019, Potential of marine natural products against drug-resistant bacterial infections, Lancet Infect. Dis., 19, e237, 10.1016/S1473-3099(18)30711-4 · DOI
  177. Dash, 2021, Thanatin: an emerging host defense antimicrobial peptide with multiple modes of action, Int. J. Mol. Sci., 22, 10.3390/ijms22041522 · DOI
  178. Piller, 2022, Membrane Activity of LL-37 derived antimicrobial peptides against Enterococcus hirae: superiority of SAAP-148 over OP-145, Biomolecules, 12, 10.3390/biom12040523 · DOI
  179. Le, 2022, Efficiency of antimicrobial peptides against multidrug-resistant staphylococcal pathogens, Front. Microbiol., 13, 10.3389/fmicb.2022.930629 · DOI
  180. Gajdács, 2019, The continuing threat of methicillin-resistant Staphylococcus aureus, Antibiot. (Basel), 8
  181. Tripathy, 2019, FtsZ inhibitors as a new genera of antibacterial agents, Bioorg. Chem., 91, 10.1016/j.bioorg.2019.103169 · DOI
  182. Bibens, 2023, A review of fatty acid biosynthesis enzyme inhibitors as promising antimicrobial drugs, Pharm. (Basel), 16
  183. Naclerio, 2019, Antibacterial small molecules that potently inhibit staphylococcus aureus lipoteichoic acid biosynthesis, ChemMedChem, 14, 1000, 10.1002/cmdc.201900053 · DOI
  184. Hurtová, 2024, Nitrogen-containing flavonoids─preparation and biological activity, ACS Omega, 9, 34938, 10.1021/acsomega.4c04627 · doi:10.1021/acsomega.4c04627
  185. Magaña, 2023, Restoring susceptibility to aminoglycosides: identifying small molecule inhibitors of enzymatic inactivation, RSC Med. Chem., 14, 1591, 10.1039/D3MD00226H · doi:10.1039/d3md00226h
  186. Douglas, 2023, Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections, Microb. Biotechnol., 16, 1456, 10.1111/1751-7915.14268 · DOI
  187. Chand, 2023, Staphylococcus aureus vaccine strategy: promise and challenges, Microbiol. Res., 271, 10.1016/j.micres.2023.127362 · DOI
  188. Peck, 2019, A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-Staphylococcus aureus Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers, Antimicrob. Agents Chemother., 63, 10.1128/AAC.02588-18 · DOI
  189. Atshan, 2023, Phage therapy as an alternative treatment modality for resistant staphylococcus aureus infections, Antibiot. (Basel), 12
  190. Liu, 2024, Bacteriophage therapy for drug-resistant Staphylococcus aureus infections, Front. Cell. Infect. Microbiol., 14
  191. Liu, 2024, Staphylococcus aureus Infections and Human Intestinal Microbiota, Pathogens, 13, 10.3390/pathogens13040276 · DOI · Paper page
  192. Walvekar, 2019, Self-assembled oleylamine grafted hyaluronic acid polymersomes for delivery of vancomycin against methicillin resistant Staphylococcus aureus (MRSA), Colloids Surf. B: Biointerfaces, 182, 10.1016/j.colsurfb.2019.110388 · DOI
  193. Thamilselvan, 2023, Polymer based dual drug delivery system for targeted treatment of fluoroquinolone resistant Staphylococcus aureus mediated infections, Sci. Rep., 13, 10.1038/s41598-023-38473-3 · DOI
  194. Joshi, 2023, Metal nanoparticles as inhibitors of enzymes and toxins of multidrug-resistant Staphylococcus aureus, Infect. Med., 2, 294, 10.1016/j.imj.2023.11.006 · DOI
  195. Rani, 2022, Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistant Staphylococcus aureus (MRSA), Asian J. Pharm. Sci., 17, 102, 10.1016/j.ajps.2021.11.004 · DOI
  196. Manaia, 2024, The complex interplay between antibiotic resistance and pharmaceutical and personal care products in the environment, Environ. Toxicol. Chem., 43, 637, 10.1002/etc.5555 · DOI
  197. Mondemé, 2023, Treatment of bacterial infections with β-lactams: cooperation with innate immunity, Infect. Immun., 91, 10.1128/iai.00503-22 · doi:10.1128/iai.00503-22
  198. Patangia, 2022, Impact of antibiotics on the human microbiome and consequences for host health, Microbiologyopen, 11, 10.1002/mbo3.1260 · DOI · Paper page
  199. Tosi, 2024, The interplay between antibiotics and the host immune response in sepsis: from basic mechanisms to clinical considerations: a comprehensive narrative review, Antibiot. (Basel), 13

Cited by

See all 135

Metadata

Authors
Brdová, D., Ruml, T., & Viktorová, J.
Venue
Drug Resistance Updates
Publisher
Elsevier BV
Published
2024-11
Volume
77
Pages
101147
ISSN
1368-7646
Cited by
135
References
12
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.